| Roche Pharma (Schweiz) AG - Madopar LIQ 62.5, Tabletten zur Herstellung einer Suspension zum Einnehmen |
| 52377 | | 01 | | Madopar LIQ 62.5 | | Tabletten zur Herstellung einer Suspension zum Einnehmen | | N04BA02 | | Levodopa and Decarboxylase Inhibitor | | 24.02.1994 | | |
|
| Composition |
| levodopum 50.00 mg, benserazidum 12.50 mg ut benserazidi hydrochloridum, acidum citricum, amylum pregelificatum, cellulosum microcristallinum, magnesii stearas pro compresso. |
| Packungsbestandteile |
| Tabletten zur Herstellung einer Suspension zum Einnehmen | | | | | Active Agent | Dose |
|---|
| Benserazide | 12.5 mg | | Levodopa | 50 mg |
| | BAG: Active Agent | Dose |
|---|
| Benserazide | 12.5 mg | | Levodopa | 50 mg |
| | | | Inactive agents |
|---|
| Citric Acid | | Amylum Pregelificatum | | Cellulosum Microcristallinum | | Magnesii Stearas pro Compresso |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 021 | 100 Tablet(s) | 8.48 | 18.30 | B | SL | No |
|
